Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 9:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 150 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Tham Clear all
Completed Phase 3 Interventional

Improving Pain Management and Long Term Outcomes Following High Energy Orthopedic Trauma (Pain Study)

NCT01789216
View directory record Official record
Conditions
Orthopaedic Fractures
Interventions
NSAID, Gabapentinoids, placebo
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 80 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
17
States / cities
Miami, Florida • West Palm Beach, Florida • Indianapolis, Indiana + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 30, 2026, 9:27 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Opioid-Free Pain Control Regiment Following Robotic Radical Prostatectomy

NCT04939987
View directory record Official record
Conditions
Radical Prostatectomies
Interventions
Tramadol, Gabapentin, Hydrocodone-Acetaminophen, Oxycodone-Acetaminophen, Ketorolac, Acetaminophen, Ketorolac tromethamine, Ketamine
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 75 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Intramuscular Ketorolac at Two Single-Dose Regimens

NCT04763876
View directory record Official record
Conditions
Musculoskeletal Pain, Analgesia, Adverse Event
Interventions
Ketorolac Injection 15 mg, Ketorolac Injection 60 mg
Drug
Lead sponsor
William Beaumont Army Medical Center
Federal
Eligibility
18 Years to 55 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Not applicable Interventional

Opioid Sparing Anesthesia Care for Pediatric Patients Having Tonsil Surgery

NCT06326983
View directory record Official record
Conditions
Tonsillitis, Post-operative Nausea and Vomiting (PONV), Emergence Delirium, Opioid Analgesic Adverse Reaction, Anesthesia, Pain
Interventions
Dexmedetomidine, Acetaminophen, Ketorolac, Morphine
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
3 Years to 17 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Not applicable Interventional

An Analgesia Protocol for Acute Renal Colic in the Emergency Department

NCT00504283
View directory record Official record
Conditions
Kidney Stone
Interventions
Toradol, Morphine
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 18, 2007 · Synced Oct 30, 2026, 9:27 AM EDT
Suspended Phase 3 Interventional

Ketorolac Applied by Continuous IV Infusion for Treatment of Moderately Severe Postoperative Pain Following Bunionectomy

NCT05324358
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Ketorolac Tromethamine, Morphine Sulfate, Intravenous Placebo for NTM-001, IV Placebo for Morphine
Drug · Other
Lead sponsor
Neumentum, Inc.
Other
Eligibility
18 Years to 64 Years
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Sun City, Arizona • Bakersfield, California • Canoga Park, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 1 Interventional

Toradol (Ketorolac) in Breast Surgery to Reduce Pain & Opioid Use

NCT04439396
View directory record Official record
Conditions
Breast Reduction, Breast Reconstruction
Interventions
Ketorolac Tromethamine, Saline
Drug · Other
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 4 Interventional

Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%

NCT00595543
View directory record Official record
Conditions
Acute Pseudophakic Cystoid Macular Edema
Interventions
Bromfenac, Ketorolac, Diclofenac
Drug
Lead sponsor
Bp Consulting, Inc
Network
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2009 · Synced Oct 30, 2026, 9:27 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Lidocaine vs Ketorolac for Management of Renal Colic in the Emergency Department

NCT03137498
View directory record Official record
Conditions
Renal Colic
Interventions
Lidocaine, Ketorolac
Drug
Lead sponsor
The Brooklyn Hospital Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 30, 2026, 9:27 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Sprix for Postoperative Pain Control Following Gynecologic Surgery

NCT04444830
View directory record Official record
Conditions
Post Operative Pain Control, Narcotic Use, Pelvic Organ Prolapse, Urinary Incontinence , Stress, Surgery
Interventions
Sprix
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 30, 2026, 9:27 AM EDT
Terminated Phase 2 Interventional Results available

Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma

NCT04495894
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Renal Cell Carcinoma
Interventions
Preoperative Ketorolac
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 4 Interventional Results available

Metoclopramide Versus Ketorolac for Tension-type Headache

NCT01011673
View directory record Official record
Conditions
Headache
Interventions
Metoclopramide, Ketorolac
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years to 64 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Early Phase 1 Interventional

Carboprost (Hemabate) for Fibroid Resection

NCT05518812
View directory record Official record
Conditions
Fibroid Uterus, Gynecologic Disease, Leiomyoma, Uterine
Interventions
Carboprost Tromethamine
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 30, 2026, 9:27 AM EDT
Recruiting Phase 4 Interventional

Pain Control With Ketorolac and Nerve Block After Wrist and Hand Surgery

NCT07773155
View directory record Official record
Conditions
Surgery, Upper Extremity
Interventions
Toradol, Oxycodone
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 30, 2026, 9:27 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Effectiveness of Corticosteroid vs Ketorolac Shoulder Injections

NCT04895280
View directory record Official record
Conditions
Full-thickness Rotator Cuff Tear, Rotator Cuff Tendinitis
Interventions
Ketorolac, Marcaine, Kenalog
Drug
Lead sponsor
Michael Khazzam
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Prospective Effect of Intravenous Ketorolac on Opioid Use, EBL and Complications Following Cesarean Delivery

NCT02509312
View directory record Official record
Conditions
Analgesia, Obstetrical, Postpartum Hemorrhage, Opioid Use, Nonsteroidals (NSAIDs)Toxicity, Coagulation Defect; Postpartum, Postoperative Pain, Ketorolac Adverse Reaction, Blood Loss, Postoperative
Interventions
Ketorolac, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 30, 2026, 9:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A 6 Month Study to Evaluate the Safety, Analgesic Efficacy of ACUVAIL™ (Ketorolac Tromethamine Ophthalmic Solution) 0.45%, in Post-PRK Corneal Wound Healing

NCT01193231
View directory record Official record
Conditions
Must be PRK Candidate
Interventions
Not listed
Lead sponsor
Durrie Vision
Other
Eligibility
18 Years to 39 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Total Hip Arthroplasty (THA) Lumbar Plexus Verses Periarticular

NCT02242201
View directory record Official record
Conditions
Total Hip Arthroplasty
Interventions
PNB Bupivacaine, PAI Ropivacaine, PAI liposomal bupivacaine, Epinephrine, Ketorolac
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 19, 2018 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 2 Interventional Results available

Prospective Randomized Controlled Trial for Pain Relief After Office Ureteral Stent Removal

NCT04112160
View directory record Official record
Conditions
Pain, Urinary Stone, Urinary Calculi
Interventions
Ketorolac, normal saline
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 79 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

NCT01305213
View directory record Official record
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Bevacizumab, Fosbretabulin Tromethamine, Laboratory Biomarker Analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
51
States / cities
Phoenix, Arizona • Burbank, California • Concord, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 30, 2026, 9:27 AM EDT
Terminated Phase 4 Interventional Results available

PROUD Study - Preventing Opioid Use Disorders

NCT04766996
View directory record Official record
Conditions
Anesthesia, Opioid Use
Interventions
Guided mindfulness exercises, Self-administered aromatherapy, Baby aspirin, Tylenol/Acetaminophen, Pregabalin, Prednisone, Meloxicam, Prilosec, Tramadol, Voltaren, Zofran, Pepcid, Reglan, Versed, Lidocaine, Propofol, Ancef, Tranexamic Acid (TXA), Decadron, Bupivacaine hydrochloride, Toradol
Behavioral · Other · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 30, 2026, 9:27 AM EDT
Not listed Early Phase 1 Interventional

Ketorolac Levels in Vitreous and Aqueous Samples From Patients Undergoing Combined Cataract and Pars Plana Vitrectomy Surgeries With and Without Intracameral Phenylephrine 1.0% / Ketorolac 0.3%

NCT06539637
View directory record Official record
Conditions
Cataract
Interventions
OMIDRIA (*Registered Product) {10.16 mg/mL (1% w/v) of phenylephrine and 2.88 mg/mL (0.3% w/v) of ketorolac}, Ketorolac Tromethamine {TORADOL} (0.5%) - Topical Eyedrop
Combination Product · Other
Lead sponsor
DHS Consulting
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Westbury, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 30, 2026, 9:27 AM EDT
Not listed Phase 4 Interventional

Ketorolac Sublingual vs. Fentanyl Intranasal in Pain Control for Bilateral Myringotomy and Tubes (BMT) Placement in Children

NCT02653742
View directory record Official record
Conditions
Pain, Postoperative, Otitis Media
Interventions
Ketorolac, Fentanyl
Drug
Lead sponsor
Anica Crnkovic
Other
Eligibility
8 Months to 7 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 3 Interventional

Nevanac 3-Month Safety Study With QID Dosing

NCT00332774
View directory record Official record
Conditions
Cataract
Interventions
Nepafenac ophthalmic solution 0.1%, Ketorolac Tromethamine ophthalmic solution 0.4%, Nepafenac ophthalmic suspension vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
10 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Oct 30, 2026, 9:27 AM EDT